Celgene Corporation (CELG) Given a $123.00 Price Target at J P Morgan Chase & Co

Celgene Corporation (NASDAQ:CELG) received a $123.00 price objective from J P Morgan Chase & Co in a research note issued to investors on Friday, October 27th. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. J P Morgan Chase & Co’s price objective would indicate a potential upside of 20.19% from the stock’s current price.

Several other equities research analysts also recently weighed in on CELG. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $175.00 price objective on shares of Celgene Corporation in a research report on Wednesday, August 9th. Vetr raised shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective on the stock in a research report on Wednesday, August 16th. Cantor Fitzgerald restated a “buy” rating and issued a $162.00 target price on shares of Celgene Corporation in a report on Tuesday, September 26th. BMO Capital Markets lowered their target price on shares of Celgene Corporation from $163.00 to $148.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Finally, SunTrust Banks, Inc. restated a “buy” rating and issued a $150.00 target price on shares of Celgene Corporation in a report on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the stock. Celgene Corporation currently has a consensus rating of “Buy” and an average price target of $139.64.

Celgene Corporation (CELG) opened at $102.34 on Friday. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The firm has a market cap of $80,574.02, a PE ratio of 15.99, a price-to-earnings-growth ratio of 0.79 and a beta of 1.79. Celgene Corporation has a fifty-two week low of $94.55 and a fifty-two week high of $147.17.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The business had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the previous year, the firm earned $1.58 EPS. The business’s revenue was up 10.2% on a year-over-year basis. equities research analysts predict that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Celgene Corporation (CELG) Given a $123.00 Price Target at J P Morgan Chase & Co” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://ledgergazette.com/2017/11/13/celgene-corporation-celg-given-a-123-00-price-target-by-j-p-morgan-chase-co-analysts.html.

In other news, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the transaction, the director now owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The disclosure for this sale can be found here. In the last quarter, insiders have sold 20,227 shares of company stock valued at $2,843,956. 0.95% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of the stock. Capital Counsel LLC NY lifted its holdings in Celgene Corporation by 0.4% in the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock worth $214,000 after purchasing an additional 6 shares during the period. Fort Pitt Capital Group LLC lifted its holdings in Celgene Corporation by 0.6% in the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after purchasing an additional 11 shares during the period. Sowell Financial Services LLC lifted its holdings in Celgene Corporation by 0.5% in the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 13 shares during the period. South Texas Money Management Ltd. lifted its holdings in Celgene Corporation by 0.6% in the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 15 shares during the period. Finally, Flagship Harbor Advisors LLC lifted its holdings in Celgene Corporation by 0.9% in the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock worth $253,000 after purchasing an additional 18 shares during the period. 79.16% of the stock is owned by institutional investors and hedge funds.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply